Healthcare Sales & Marketing Network News: VTE

Searching News Database: VTE

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Jul 2022
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 8 Apr 2021
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Biopharmaceuticals

HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA to Acquire Correvio
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 10 Oct 2019
FDA Clears GEKO DEVICE for Use in Non-surgical Patients at Risk for Deep Vein Thrombosis Based on Study Demonstrating a Zero Percent DVT Rate in Patients After a Stroke
Devices FDA

HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Jun 2019
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Dec 2018
Magnetic Insight Raises $18M to Support Commercial Growth of Magnetic Particle Imaging in Cell Therapy, Vascular and Oncology Applications
Devices Radiology Venture Capital Personnel

HSMN NewsFeed - 28 Aug 2018
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA(R) (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice
Biopharmaceuticals

HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology

HSMN NewsFeed - 13 Aug 2018
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA(R) (edoxaban)
Biopharmaceuticals

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 Apr 2018
Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 29 Mar 2018
Inari Medical Announces Completion of $27 Million Series C Financing
Devices Interventional Venture Capital

HSMN NewsFeed - 23 Mar 2018
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Dec 2017
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2017
ManaMed Inc. Introduces PlasmaFlow, The World's First FDA-Approved Digital and Tubeless Deep Vein Thrombosis Prevention Device
Devices Product Launch

HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 3 Apr 2017
Sucampo Acquires Vtesse Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Jan 2017
Vtesse Announces Appointment of Jason Meyenburg as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Nov 2016
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Biopharmaceuticals

HSMN NewsFeed - 27 May 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Biopharmaceuticals

HSMN NewsFeed - 2 Mar 2016
Firstkind Seeks Global Distribution Partners to Extend geko(TM) Device Roll-out
Devices Distribution

HSMN NewsFeed - 30 Nov 2015
Boston Scientific Receives FDA Approval And CE Mark For AngioJet(TM) ZelanteDVT(TM) Thrombectomy Catheter
Devices Interventional FDA Regulatory

HSMN NewsFeed - 22 Oct 2015
Vtesse, Inc. Expands Scientific Advisory Board and Appoints New VP of Clinical Operations to Support Late-Stage Clinical Study of Lead Drug Candidate VTS-270
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Aug 2015
NICE Recommends Once-daily Lixiana(R) (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 5 Dec 2014
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
Biopharmaceuticals Product Launch

HSMN NewsFeed - 19 Nov 2014
Argon Medical's CLEANER XT(TM) and CLEANER 15(TM) Rotational Thrombectomy Systems Receive FDA Clearance for Mechanical Declotting and Infusion in the Peripheral Vasculature
Devices Interventional FDA

HSMN NewsFeed - 15 Jul 2014
Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory

HSMN NewsFeed - 31 Mar 2014
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Mar 2014
AngioDynamics Receives Expanded FDA Clearance for AngioVac
Devices Cardiology FDA

HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2013
AngioDynamics Achieves CE Approval for AngioVac
Devices Surgery Cardiology

HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Jul 2013
Instrumentation Laboratory Launches HemosIL(R) FDP Assay In Europe, Asia And Other International Regions
Diagnostics Product Launch

HSMN NewsFeed - 10 Apr 2013
Kaleidoscope Medical Secures Series A Funding
Devices Venture Capital

HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Dec 2012
Regado Biosciences, Inc. Secures $51 Million Series E Financing
Biopharmaceuticals Cardiology Venture Capital

HSMN NewsFeed - 4 Dec 2012
Vascular Closure Systems, Inc. Announces the Successful Completion of the First in Human (FIH) Clinical Trial of the 6 Fr. / 7 Fr. FastSeal(R) Bioabsorbable Vascular Access Closure System
Devices Interventional Cardiology

HSMN NewsFeed - 25 Jun 2012
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS(R) (apixaban)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals

HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Biopharmaceuticals

HSMN NewsFeed - 31 May 2011
Medical Compression Systems Receives FDA Clearance for New 'Prevention and Detection' Product
Devices FDA

HSMN NewsFeed - 20 May 2011
ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Biopharmaceuticals Surgery Orthopaedic

HSMN NewsFeed - 22 Apr 2011
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Biopharmaceuticals Surgery Regulatory

HSMN NewsFeed - 4 Nov 2010
Covidien Receives FDA 510(k) Clearance for Kendall SCD(TM) Compression Comfort Sleeve and Kendall SCD(TM) 700 Series Controller
Devices FDA

HSMN NewsFeed - 31 Aug 2010
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals

HSMN NewsFeed - 23 Feb 2010
Instrumentation Laboratory Receives 510(K) Clearance From FDA and Canadian License for HemosIL(R) D-Dimer HS 500 Assay
Diagnostics FDA Regulatory

HSMN NewsFeed - 18 Nov 2009
Basilea's Toctino(R) receives marketing authorization in Canada
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Oct 2009
Basilea's Toctino(R) receives marketing authorization in Switzerland
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 23 Sep 2009
Cook Medical's Advanced NavAlign Delivery System for IVC Filters Adds Procedural Speed, Control and Accuracy
Devices

HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals

HSMN NewsFeed - 5 May 2009
Basilea's Toctino(R) receives marketing authorization in Spain
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 29 Apr 2009
Basilea's Toctino(R) Receives Marketing Authorization in Netherlands
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology

HSMN NewsFeed - 17 Mar 2009
Basilea's Toctino(R) receives marketing authorization in Austria
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 11 Mar 2009
Basilea's Toctino(R) Receives Marketing Authorization in Belgium and Luxemburg
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 24 Feb 2009
Basilea Pharmaceutica files claims against Johnson&Johnson over its handling of ceftobiprole (ZEFTERA(TM)/Zevtera(TM)) clinical studies
Biopharmaceuticals Litigation

HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Nov 2008
Zevtera(TM) (ceftobiprole medocaril), the novel anti-MRSA broad-spectrum antibiotic, receives a positive opinion from the CHMP
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Sep 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Aug 2008
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay
Diagnostics FDA

HSMN NewsFeed - 30 Jul 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jul 2008
Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
Devices Interventional

HSMN NewsFeed - 30 May 2008
Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Biopharmaceuticals Orthopaedic Surgery

HSMN NewsFeed - 20 May 2008
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection from Cervical Disease than the Pap
Diagnostics

HSMN NewsFeed - 14 May 2008
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Mar 2008
Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jan 2008
Clexane(R)/Lovenox(R) Approved in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Dec 2007
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery

HSMN NewsFeed - 9 Oct 2007
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
Diagnostics FDA

HSMN NewsFeed - 23 Jul 2007
Court Dismisses Gen-Probe Court Action Against Digene
Diagnostics Litigation

HSMN NewsFeed - 11 Jul 2007
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Biopharmaceuticals

HSMN NewsFeed - 8 Jul 2007
Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Biopharmaceuticals

HSMN NewsFeed - 8 Jul 2007
New Study Shows That Extending Prophylaxis With Clexane(R) / Lovenox(R) (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Biopharmaceuticals

HSMN NewsFeed - 19 Jun 2007
Beckman Coulter, Inc. Dismissed in Case Against Ventana Medical Systems, Inc.
Diagnostics Litigation

HSMN NewsFeed - 3 Jun 2007
QIAGEN and Digene Announce Merger Creating Market and Technology Leader In Molecular Diagnostics
Diagnostics Oncology Mergers & Acquisitions

HSMN NewsFeed - 10 May 2007
Preliminary Injunction Denied in Digene's Case Against Ventana Medical Systems
Diagnostics Litigation

HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Apr 2007
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
Biopharmaceuticals

HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 4 Apr 2007
Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
Biopharmaceuticals

HSMN NewsFeed - 25 Mar 2007
Data Shows That Omission of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Medical Patients Is Frequent and Leads to Higher Risk of Deep-Vein Thrombosis (DVT)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 7 Feb 2007
FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
Biopharmaceuticals Cardiology

HSMN NewsFeed - 1 Feb 2007
Sanofi-aventis Applauds New National Standards for Prophylaxis of Venous Thromboembolism in Surgical Patients
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
New Study Shows Clexane(R) / Lovenox(R) (Enoxaparin Sodium Injection) is More Effective Than Unfractionated Heparin (UFH) for Preventing the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 11 Dec 2006
Positive Phase 3 Results for New Fixed Oral Dose Anticoagulant Presented at 48th Annual Meeting of the American Society of Hematology
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2006
Daryl J. Faulkner Appointed Chief Executive Officer and Director of Digene
Diagnostics Personnel

HSMN NewsFeed - 13 Nov 2006
Auriga Laboratories Appoints Charles R. Bearchell as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2006
Instrumentation Laboratory Receives FDA Clearance for Homocysteine Assay
Diagnostics FDA

HSMN NewsFeed - 27 Oct 2006
James Godsey, Ph.D., to Join Digene as Senior Vice President Research and Development
Diagnostics Personnel

HSMN NewsFeed - 10 Oct 2006
CardioVascular Technologies, Inc. Announces Patent Notice of Allowance for Its Sutureless Anastomosis Coupler Technology - System Enables Clampless Coronary Artery Bypass Graft (CABG) Surgery
Devices Cardiology

HSMN NewsFeed - 2 Oct 2006
FDA Grants Priority Review for ARIXTRA(R) (fondaparinux sodium) in the Treatment of Acute Coronary Syndromes
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 28 Sep 2006
California to Require Insurers to Cover HPV Testing in Cervical Cancer Screening
Diagnostics Oncology Reimbursement

HSMN NewsFeed - 19 Sep 2006
CardioVascular Technologies, Inc. Announces Patent Notice of Allowance for its Rapid Exchange (RX) Catheter Platform with Stent Deployment Features Technology
Devices Interventional Cardiology

Return to NewsFeed

Additional items found! 56

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 56 additional stories matching:
VTE
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.